These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11909903)

  • 1. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
    Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Poewe W
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):430. PubMed ID: 11909897
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
    Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
    Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
    Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
    Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
    Wohlfarth K; Kampe K; Bigalke H
    Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
    Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
    Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
    Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A therapy for cervical dystonia.
    Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
    Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
    J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
    Naumann M; Yakovleff A; Durif F;
    J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
    Rystedt A; Nyholm D; Naver H
    Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
    Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
    Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
    Wenzel R; Jones D; Borrego JA
    J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type A therapy for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003633. PubMed ID: 15674910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.